Trutakna (atacicept-vymj), a first-in-class dual BAFF and APRIL inhibitor, secured FDA accelerated approval to reduce proteinuria in adults with primary IgA nephropathy, supported by data ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results